[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368484-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368484-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","shared-neoantigens-atlas-for-off-the-shelf-cancer-vaccine-development","Shared neoantigens’ atlas for off-the-shelf cancer vaccine development","","Shared neoantigens can support off-the-shelf cancer vaccines by being common across patients and presented by widespread HLA alleles. This study extends prior work by analyzing shared mutated neoantigens derived from SNVs and InDels across 50 HLA haplotypes in MHC class I loci, including proteins found in at least 5% of cancer patients. The extended atlas identifies 15 SNV-neoantigens and 55 InDel-neoantigens with improved predicted affinity and proposes global or regional therapeutic vaccine coverage across multiple cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/shared-neoantigens-atlas-for-off-the-shelf-cancer-vaccine-development/368484/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/shared-neoantigens-atlas-for-off-the-shelf-cancer-vaccine-development/368484.png","ImageObject",300,407,{"name":42,"@type":43},"Maya Linwood","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study expand compared with earlier work on shared neoantigens?","Question",{"text":63,"@type":64},"It expands the analysis of shared mutated neoantigens by covering 50 haplotypes across three MHC class I loci, rather than a smaller set of haplotypes previously analyzed.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many shared neoantigens are identified for SNVs and InDels?",{"text":68,"@type":64},"The study identifies 15 shared SNV-neoantigens and 55 shared InDel-neoantigens, with significant predicted affinity improvements versus the corresponding wild-type.",{"name":70,"@type":61,"acceptedAnswer":71},"Which cancers and coverage patterns are suggested for off-the-shelf vaccine development?",{"text":72,"@type":64},"Therapeutic vaccines based on shared mutated SNV and InDel neoantigens may be developed with global coverage for COAD, STAD, and UCEC, and with regional coverage for PAAD and UVM, based on HLA haplotype distribution.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368484,1790211536,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Mauriello et al.  \nJournal of Translational Medicine (2025) 23:558 [https://doi.org/10.1186/s12967-025-06478-3](https://doi.org/10.1186/s12967-025-06478-3)  \nJournal of Translational Medicine  \n RESEARCH Open Access  \nShared neoantigens’ atlas for off-the-shelf cancer vaccine development  \nAngela Mauriello 1†, Beatrice Cavalluzzo1†, Concetta Ragone 1, Maria Tagliamonte1* and Luigi Buonaguro 1*  \nAbstract  \nBackground We have recently described that the most prevalent 100 mutations identified in human cancers,  \nboth single nucleotide variations (SNVs) and InDels, generate a handful number of shared mutated neoantigens (SNVand InDel-NeoAgs) in association with 5 HLA-A and 7 B haplotypes.  \nMethods In the present study, we expanded such analysis to 50 haplotypes in the three MHC class I loci (10 HLA-A, 27 HLA-B and 13 HLA-C), including all the mutated proteins identified in at least 5% of cancer patients.  \nResults Overall, the extended analysis identified 15 SNV-NeoAgs and 55 InDel-NeoAgs with a significant affinity improvement over the corresponding wt (DAI > 10) . These targetable shared NeoAgs are prevalently derived from PIK3CAH1047R (6/15 SNV-NeoAgs) and LARP4BT163Hfs (30/55 InDel-NeoAgs) . From the HLA perspective, the HLAA*33:03 is associated with the largest number of SNV-NeoAgs (4/15 NeoAgs) and the HLA-B*58:01 is associated with the largest number of InDel-NeoAgs (16/55 NeoAgs) .  \nAccording to the distribution of each HLA haplotype in at least 10% of the regional populations, therapeutic cancer vaccines based on mutated shared SNV and InDel-NeoAgs, might be developed for COAD, STAD and UCEC cancers, with a global coverage, and for PAAD and UVM, with a regional coverage.  \nConclusions This represents the first in-depth analysis for the identification of a specific repertoire of shared mutated NeoAgs, most of which never reported before. Such shared SNV and InDel-NeoAgs are indispensable for the development of “off-the-shelf” cancer vaccines targeting a relevant percentage of cancers in a significant percentage of cancer patients worldwide.  \nKeywords Mutations, Shared neoantigens, Off-the-shelf cancer vaccines, T cell immunity  \nIntroduction  \nDriver mutations in specific proteins confer a growth advantage on the cellular survival or proliferation, possibly leading to transformation and cancer development [1–5]. Single nucleotide variants (SNVs), occurring at the  \n†Angela Mauriello and Beatrice Cavalluzzo have contributed equally to this work.  \n*Correspondence:  \nMaria Tagliamonte [m.tagliamonte@istitutotumori. na.it](m.tagliamonte@istitutotumori. na.it)[ ](m.tagliamonte@istitutotumori. na.it)Luigi Buonaguro  \nl.buonaguro@istitutotumori. na.it  \n1 Innovative Immunological Models Unit, Istituto Nazionale Tumori IRCCS –“Fond G. Pascale”, Via Mariano Semmola, 52, Naples, Italy  \nfirst or second position of the codon, may result into a single amino acid substitution in the protein sequence (nonsynonymous change or a missense variant). Short insertions or deletions (InDels), if not a multiple of three bp, will result in a frameshift and a complete change in the reading frame of the downstream sequence of the gene. This will alter the product of translation, potentially leading to targeted decay of the alternative mRNA [6–8]. The resulting SNV or InDel mutation may fall in a peptide generated by the proteasome and loaded onto major histocompatibility complex (MHC) class I molecules by the transporter associated with antigen processing (TAP). When the peptide carrying the mutation is compatible with the cellular HLA allele, the stable peptide-MHC  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence,","cbCaifGpmU1yk7cc","https://ap.wps.com/l/cbCaifGpmU1yk7cc","pdf",9288874,29,"English","# Abstract\n# Introduction\n## Driver mutations and neoantigen generation\n## Role of HLA presentation and T-cell immunity","[{\"question\":\"What does the study expand compared with earlier work on shared neoantigens?\",\"answer\":\"It expands the analysis of shared mutated neoantigens by covering 50 haplotypes across three MHC class I loci, rather than a smaller set of haplotypes previously analyzed.\"},{\"question\":\"How many shared neoantigens are identified for SNVs and InDels?\",\"answer\":\"The study identifies 15 shared SNV-neoantigens and 55 shared InDel-neoantigens, with significant predicted affinity improvements versus the corresponding wild-type.\"},{\"question\":\"Which cancers and coverage patterns are suggested for off-the-shelf vaccine development?\",\"answer\":\"Therapeutic vaccines based on shared mutated SNV and InDel neoantigens may be developed with global coverage for COAD, STAD, and UCEC, and with regional coverage for PAAD and UVM, based on HLA haplotype distribution.\"}]","Shared neoantigens’ atlas for off-the-shelf cancer vaccine development | PDF",1790177201,73,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/644013ba243bb70fbf44a3e2b498664d.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0484df30d2c43fa26ff4cf9e91ae2923.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/985167ab00b04adc85ebbae3c3a94084.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f6a4d20f7e98d527f6eec05a7bf07a2.webp",980,1301]